• UCLA Health
  • myUCLAhealth
  • School of Medicine
U Magazine

U Magazine

U Magazine
  • Home
  • Current Issue
  • Centennial Campaign for UCLA Issue
  • Browse U Magazine
  • Letters to the Editor
  • Subscribe
  • Contact
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

U Magazine

Browse U Magazine

  1. Home
  2. Browse U Magazine
Share this
Faculty

Dr. Slamon's Perspective

UCLA Medicine Fall 2009-Dr Dennis SlamonWHEN THE U.S. FOOD & DRUG ADMINISTRATION approved the use of Herceptin to treat advanced breast cancer 11 years ago, Dennis Slamon, M.D., predicted that the new therapy would someday become one arrow in a quiver of molecularly focused drugs that target tumor cells, while leaving healthy cells alone. It appears that he was right.

Dr. Slamon has a good vantage point from which to view recent developments. His research at UCLA directly led to the development of Herceptin, and has earned him worldwide recognition, including more than two-dozen national and international awards. Today, Herceptin is accepted as the standard of care for the 20 percent of women with breast cancer who have the HER2 mutation. And Dr. Slamon is confident that new treatments deriving from clinical trials now underway will offer even more potent therapies. “The one-size-fits-all approach for the major cancers, including and especially for breast cancer, was not as effective as it could have been,” says Dr. Slamon, who is the director of clinical/translational research at UCLA’s Jonsson Comprehensive Cancer Center. “What we’ve been doing here is trying to design therapies very specifically for what’s driving the cancer and develop something that is more effective and less toxic.”

In the 11 years since it was approved, Herceptin has been tested against breast cancer in clinical trials with different chemotherapy combinations. In two studies, one pairing Herceptin with Avastin, a drug that attacks tumors by inhibiting the growth of new blood vessels, and one combining it with an inhibitor of the epidermal growth factor receptor, Tarceva, chemotherapy was removed from the mix entirely. And Herceptin is currently being tested in a large international trial paired with chemotherapy and Avastin.

In early-stage breast cancer trials, Herceptin paired with chemotherapy significantly increased disease-free survival time. The study also tested Herceptin with a chemotherapy combination that eliminated Adriamycin, an anthracycline that is commonly used to treat breast cancer but which, when used with Herceptin, can cause heart damage. That altered regimen also significantly improved disease-free survival.

Oncologists have been reluctant to remove Adriamycin from their arsenal, but Dr. Slamon says that his study definitively proved it is possible to get the same result without it, which may lead to yet another paradigm shift in treatment for breast cancer.

The Herceptin-Avastin and Herceptin-Tarceva studies also have been promising. But UCLA oncologists are most excited to see results from the large international study.

Ultimately, Dr. Slamon says, “we hope these studies will lead to another very effective treatment option for women with breast cancer.”


Previous
Comfort Measures
Next
Award/Honors


YOU ARE VIEWING

Fall 2009

Fall 2009
E-Brochure
Printable PDF
IN THIS ISSUE
  • 15 YEARS
  • The Sounds of Learning
  • Rethinking Alzheimer's Disease
  • Learning to Walk Again
  • Return of the jazz Singer
  • New Dean Named
  • How to Build a Bigger Brain
  • Protecting Med Students from Influences of Pharma
  • Chain of Life
  • Transplantation Milestones
  • More Obesity Blues
  • Dr. Daniel Geschwind
  • Do No Harm
  • The Surgeon Scientist
  • Comfort Measures
  • Dr. Slamon's Perspective
  • Award/Honors
  • Rock On!
  • A Toast from Classes Past
  • Cheers to the Classes of ’55-’60, ’70, ’80, ’90 and ’00
  • Come One, Come All
  • Give Back
  • Welcome Back, Donald
  • Supper Time
  • The Dean's Visit
  • Visionaries
  • Gifts
  • Events
  • Chairs of Distinction
  • Memories of Marwa
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest

Sign in to myUCLAhealth

Learn more about myUCLAhealth